Click here to go to the previous page
Concurrent CT/RT and Post-Op Radiotherapy for Head and Neck Cancer
Program Code:
EDU305
Date:
Tuesday, September 23, 2008
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Dr. Matthew Fury received his bachelor's of science in biology from the University of North Carolina at Chapel Hill, followed by receiving his Ph.D. in cellular and molecular biologyand and his M.D. from the State University of New York. His area of expertise is in head and neck cancers.
|
Nancy Lee, Radiation Oncologist, Memorial Sloan-Kettering Cancer Center
David Pfister, Chief of the Head and Neck Medical Oncology Service,
Memorial Sloan-Kettering Cancer Center
Dr. Pfister is an internationally recognized expert in the management of head and neck tumors. He is Chief of the Head and Neck Medical Oncology Service and co-Chair of the Head and Neck Cancer Disease Management Team at Memorial Sloan-Kettering Cancer Center; he holds the rank of Professor of Medicine at Weill Medical College of Cornell University. His research interests include the development and evaluation of combined modality, “organ preservation” therapies; prognostic risk stratification; drug development; and outcome/quality of care assessment. He is co-Chair of the Recurrent/Metastatic Disease Task Force for the Head and Neck Cancer Steering Committe at the National Cancer Institute (NCI). Dr. Pfister has also figured prominently in the development and assessment of clinical practice guidelines as a way to improve the quality of care within oncology, currently holding leadership positions both within the National Comprehensive Cancer Network (NCCN), where he serves on the Board of Directors, and the American Society of Clinical Oncology (ASCO). He is the current co-chair of ASCO’s Larynx Preservation Guideline Panel, and former co-chair of the Society’s Unresectable Lung Cancer Guideline Panel. He is a former chair of ASCO’s Health Services Research Committee, as well as of the Program Committee’s, Head and Neck Cancer subcommittee. Dr. Pfister serves on the Editorial Boards of the Journal of Clinical Oncology, Clinical Cancer Research, and Critical Reviews in Oncology/Hematology.
|
LEARNER OUTCOMES:
-
Compare whether altered fractionation plus concurrent chemotherapy is better than standard fractionation with the same chemotherapy regimen.
-
Discuss the evidence for using concurrent chemoradiotherapy in both the definitive as well as the post-operative setting.
-
Discuss toxicity associated with the use of concurrent chemoradiotherapy.